Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients

American Journal of Health-System Pharmacy

Volumn 62, Issue 8, 2005, Pages 809-815

  Scott, James D ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Antiretroviral agents; Blood levels; Combined therapy; Compliance; Dosage schedules; Drugs, availability; HIV infections; Patients; Pharmacokinetics; Resistance; Ritonavir; Toxicity

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; EFAVIRENZ; GLYCOPROTEIN P; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TENOFOVIR;

ASTHENIA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; DRUG SAFETY; DYSLIPIDEMIA; FLANK PAIN; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; NEPHROLITHIASIS; NEPHROTOXICITY; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; VIRUS RESISTANCE;

EID: 17444392426     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/62.8.809     Document Type: Review

References (59)

1. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/guidelines/adult/AA_032304.pdf (accessed 2004 Sep 17).
2. Yeni PG, Hammer SM, Hirsch MS et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society - USA Panel. JAMA. 2004;292:251-65.
3. Bodasing N, Fox R. HIV-associated lipodystrophy syndrome: description and pathogenesis. J Infect. 2003; 46:149-54.
4. Loutfy MR, Walmsley SL. Salvage antiretroviral therapy in HIV infection. Expert Opin Pharmacother. 2002; 3:81-90.
5. Van Praag RM, Wit FW, Jurriaans S et al. Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy. AIDS. 2002; 16:719-25.
6. Baxter JD, Mayers DL, Wentworth DN et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS. 2000; 14:F83-93.
7. Durant J, Clevenbergh P, Halfon P et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999; 353:2195-9 (erratum: Lancet. 1999; 354:1128).
8. Hirsch MS, Brun-Vezinet F, Clotet B et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society - USA Panel. Clin Infect Dis. 2003; 37:113-28.
9. Deeks SG. Determinants of virological response to antiretroviral therapy: implications for long-term strategies. Clin Infect Dis. 2000; 30(suppl 2):S177-84.
10. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133:21-30.
11. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS. 2000; 14:237-42.
12. Van Asperen J, Van Tellingen O, Beijnen JH. The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol Res. 1998; 37:429-35.
13. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother. 2004; 53:4-9.
14. Kurowski M, Kaeser B, Sawyer A et al. Low-dose ritonavir moderately enhances nelfinavir exposure. Clin Pharmacol Ther. 2002; 72:123-32.
15. Zolopa AR, Shafer RW, Warford A et al. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med. 1999; 131:813-21.
16. Atkinson B, Isaacson J, Knowles M et al. Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine. J Infect Dis. 2000; 182:420-7.
17. DeGruttola V, Dix L, D'Aquila R et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther. 2000;5:41-8.
18. Kempf DJ, King MS, Bernstein B et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis. 2004; 189:51-60.
19. Macmanus S, Yates P, White S et al. GW433908 in ART-naive subjects: absence of resistance at 48 weeks with boosted regimen and APV-like resistance profile with unboosted regimen. www.retroconference.org/2003/AbstractAbstract. aspx?AbstractID=1424 (accessed 2004 Mar 25).
20. Eron JJ, Feinberg J, Kessler HA et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis. 2004; 189:265-72.
21. Molina JM, Gathe J, Lim PL et al. Comprehensive resistance testing in antiretroviral naive patients treated with once-daily lopinavir/ritonavir plus tenofovir and emtricitabine: 48-week results from study 418. www.ias.se/ejias/print.asp?abstract_id=2171864 (accessed 2005 Jan 13).
22. Coffey S. Options for once-daily dosing of antiretrovirals. www.hivinsite.com/InSite?page=md-rr-19 (accessed 2004 Jan 22).
23. Badaro R, DeJesus E, Lazzarin A et al. Efficacy and safety of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) vs lopinavir/ritonavir (LPV/RTV) in combination with tenofovir (TFV) and one NRTI in patients who have experienced virologic failure to multiple HAART regimens: 16-week results from BMS AI424-045. Antivir Ther. 2003; S212-3. Abstract.
24. Soria A, Gianotti N, Cernuschi M et al. Once-daily saquinavir and ritonavir in treatment-experienced HIV-1-infected individuals. New Microbiol. 2004; 27:11-5.
25. DeJesus E, LaMarca A, Sension M et al. The Context study: efficacy and safety of GW 433908/RTV in PI-experienced subjects with virological failure (24 week results). www.retroconference.org/2003/Abstract/Abstract.aspx?AbstractID= 286 (accessed 2003 May 15).
26. Vertex Pharmaceuticals Incorporated. Vertex reports preliminary 48-week data from Phase III study of 433908, an investigational HIV protease inhibitor. www.vpharm.com/Pressreleases2003/pr072403.html (accessed 2004 Jun 4).
27. min is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. J Acquir Immune Defic Syndr. 2002; 29:374-7.
28. Lamotte C, Peytavin G, Perre P et al. Increasing adverse events (AE) with indinavir (IDV) dosages and plasma concentration in four different ritonavir (RTV)-IDV-containing regimens in HIV-infected patients. www.retroconference.org/ 2001/abstracts/abstracts/abstracts/738.htm (accessed 2001 Apr 26).
29. Boyd M, Duncombe C, Ruxrungthram K et al. Indinavir TID vs indinavir/ritonavir BID in combination with AZT/3TC for HIV infection in nucleoside pretreated patients: HIV-NAT 005 76-week follow up. http://63.126.3-84/2002/Abstract/13001.htm (accessed 2002 May 17).
30. Arnaiz JA, Mallolas J, Podzamczer D et al. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS. 2003; 17:831-40.
31. Dietrich MA, Butts JD, Raasch RH. HIV-1 protease inhibitors: a review. Infect Med. 1999; 16:716-38.
32. Van Heeswijk RP, Veldkamp A, Mulder JW et al. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther. 2001; 6:201-29.
33. Juette A, Salzberger B, Franzen C et al. Increased morbidity from severe coronary heart disease in HIV-patients receiving protease inhibitors. www.retroconference.org/99/abstracts/656.htm (accessed 2004 Jul 23).
34. Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med. 1999; 131:548. Letter.
35. Krishnaswamy G, Chi DS, Kelley JL et al. The cardiovascular and metabolic complications of HIV infection. Cardiol Rev. 2000; 8:260-8.
36. Rhew D, Kim M, Bernal M et al. Association between protease inhibitors and increased cardiovascular risk: a systematic review. Antivir Ther. 2002; 7:L38. Abstract.
37. Holmberg SD, Moorman AC, Williamson JM et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet. 2002; 360:1747-8.
38. Iloeje U, Yuan Y, Tuomari A et al. Protease inhibitors may increase risk of cardiovascular disease in HIV-infected patients. www.retroconference.org/ 2003/Abstract/Abstract.aspx?AbstractID=630 (accessed 2004 Jul 23).
39. Mary-Krause M, Cotte L, Simon A et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479-86.
40. Periard D, Telenti A, Sudre P et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation. 1999; 100:700-5.
41. Penzak SR, Chuck SK. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis. 2000; 32:111-23.
42. Buss N, Snell P, Bock J et al. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharmacol. 2001; 52:255-64.
43. Walmsley S, Bernstein B, King M et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002; 346:2039-46.
44. Calza L, Manfredi R, Farneti B et al. Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy. Int J Antimicrob Agents. 2003;22:54-9.
45. Gutierrez F, Padilla S, Navarro A et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopiriavir/ritonavir- containing regimens. J Acquir Immune Defic Syndr. 2003; 33:594-600.
46. Dragsted UB, Gerstoft J, Pedersen C et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin 1 trial. J Infect Dis. 2003;188:635-42.
47. Walmsley SL, Benetucci J, Brutus A et al. Lipid profiles of patients enrolled in the MaxCmin 2 trial: a randomized, open-label multi-center comparative trial evaluating the safety and efficacy of lopinavir/ritonavir (400/100 mg twice daily) vs saquinavir/ritonavir SQV/r (1000/100 mg twice daily). www.retroconference.org/2004/cd/Abstract/720.htm (accessed 2004 May 24).
48. Temesgen Z. Current status of antiretroviral therapies. Expert Opin Pharmacother. 2001; 2:1239-46.
49. Gisolf EH, van Heeswijk RP, Hoetelmans RW et al. Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir. AIDS. 2000; 14:801-5.
50. Feinberg J, Brun S, Xu Y et al. Durable suppression of HIV+ RNA after 2 years of therapy with ABT-378/ritonavir (ABT-378/r) treatment in single protease inhibitor experienced patients. AIDS. 2000; 14:546. Abstract.
51. Danner S, Brun S, Sylte J et al. Paper presented at 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2001 Dec 16-19.
52. De Mendoza C, Martín-Carbonero L, Barreiro P et al. Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families. HIV Clin Trials. 2002; 3:304-9.
53. Boffito M, Arnaudo I, Raiteri R et al. Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS. 2002;16:2081-3.
54. Arvieux C, Tattevin P, Souala FM et al. Salvage therapy with amprenavir and ritonavir: prospective study in 17 heavily pretreated patients. HIV Clin Trials. 2002; 3:125-32.
55. Schooley R, Haubrich R, Sension M et al. Paper presented at 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2001 Dec 16-19.
56. DeJesus E, Grinsztejn B, Rodriguez C et al. Efficacy and safety of atazanavir with ritonavir or saquinavir vs lopinavir/ritonavir in patients who have experienced virologic failure on multiple HAART regimens: 48-week results from BMS A1424-045. www.retroconference.org/2004/cd/Abstract/547.htm (accessed 2004 Mar 23).
57. Sanne I, Piliero P, Squires K et al. Results of a Phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003; 32:18-29.
58. Haas DW, Zala C, Schrader S et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy, a randomized comparative pilot trial. AIDS. 2003; 17:1339-49.
59. Murphy RL, Sanne I, Cahn P et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003; 17:2603-14.